Patents Examined by Robert A. Wax
  • Patent number: 10688058
    Abstract: The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: June 23, 2020
    Assignee: Impax Laboratories, LLC
    Inventors: Ann Hsu, Liang Dong, Amy Ding, Suneel Gupta
  • Patent number: 10688184
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: June 23, 2020
    Assignee: ACURA PHARMACEUTICALS, INC.
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Patent number: 10688057
    Abstract: A dosage form comprising a capsule containing one or more tablets of 5-aminosalicylic acid or a salt thereof as an active ingredient where each of the one or more tablets is enterically coated is disclosed.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: June 23, 2020
    Assignee: Allergan Pharmaceuticals International Limited
    Inventors: Emma Boyd, Deborah Leigh Caldwell, Catherine Coulter, Ryan Loughlin, Stephen McCullagh
  • Patent number: 10682318
    Abstract: The subject invention provides materials methods for reducing infections in subjects. The materials methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to be possible.
    Type: Grant
    Filed: June 22, 2019
    Date of Patent: June 16, 2020
    Assignee: INNOVATION TECHNOLOGIES, INC.
    Inventors: Carolyn L. Twomey, Gareth Clarke, Samuel Zaidspiner
  • Patent number: 10682338
    Abstract: Method of treating bacterial vaginosis in a subject in need thereof involving administering to the subject a therapeutically effective amount of secnidazole in a microgranule formulation, wherein the microgranule formulation comprises a plurality of microgranules having a volume-weighted particle size distribution within a microgranule population, wherein the volume-weighted particle size distribution as measured from a representative sample of the microgranule population comprises (a) 10% of the microgranule population having a volume-weighted particle size about no less than 470 micrometers; (b) 50% of the microgranule population having a volume-weighted particle size between about no less than 640 micrometers and about no more than 810 micrometers; (c) 90% of the microgranule population having a volume-weighted particle size about no more than 1170 micrometers; or (d) a combination thereof, which can include some or all of (a) through (c) above.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: June 16, 2020
    Assignee: Lupin Inc.
    Inventors: Helen S. Pentikis, David Palling, Carol J. Braun, Richard Holl
  • Patent number: 10682436
    Abstract: Systems and methods related to polymer foams for the treatment of blood vessel dissections are generally described. Some embodiments relate to compositions and methods for the preparation of polymer foams, and methods for using the polymer foams. The polymer foams can be applied to or within a dissection caused by an intimal tear in a blood vessel, sealing the dissection and preventing further perfusion thereof. In some embodiments, the polymer foam can be formed within a body cavity (i.e., in-situ foam formation). The foam may be used to fill the dissection as a thrombosing agent. In addition, the foam may be used in conjunction with medical devices such as stents, stent-grafts, balloons, and catheters.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 16, 2020
    Assignee: Arsenal Medial, Inc.
    Inventors: Toby Freyman, Meghan McGill
  • Patent number: 10675247
    Abstract: A press coated tablet for delayed release of an active ingredient comprising: (a) a core comprising one or more active ingredients, and; (b) an erodible delayed release barrier surrounding the core and comprising a wax and two or more grades of L-HPC, wherein the wax and L-HPC are provided in a weight ratio of wax to L-HPC of from 30%:70% to 70%:30%. The invention also relates to a method of making the press coated tablet.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: June 9, 2020
    Assignee: Drug Delivery International Ltd.
    Inventors: Howard Norman Ernest Stevens, Alexander Balfour Mullen, David Smith, Fiona Jane Macdougall, Vivekanand Bhardwaj
  • Patent number: 10668081
    Abstract: Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: June 2, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Patrick M. Hughes, Jie Shen, Michael R. Robinson, David F. Woodward, Robert M. Burk, Hui Liu, Jinping Wan, Chandrasekar Durairaj, Gyorgy F. Ambrus, Ke Wu, Danny T. Dinh
  • Patent number: 10668079
    Abstract: The present disclosure provides a composition consisting of ceftriaxone sodium and sulbactam sodium, a pharmaceutical formulation comprising the same and the application thereof. The composition is characterized by having an X-ray powder diffraction pattern with peaks at specific angles. The pharmaceutical formulation according to the present disclosure have better antibacterial activity and stability compared with known compositions, and are thus very suitable for the treatment of bacterial infections, especially for the treatment of refractory urogenital system infections caused by Neisseria gonorrhoeae which has drug-resistance to a variety of antibiotics (?-lactams, tetracyclines, macrolides, fluoroquinolones and aminoglycosides).
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: June 2, 2020
    Assignees: XIANGBEI WELMAN PHARMACEUTICAL CO., LTD., GUANGZHOU WELMAN NEW DRUG R&D CO., LTD., NANJING KANGFUSHUN PHARMACEUTICAL CO., LTD.
    Inventor: Mingjie Sun
  • Patent number: 10668037
    Abstract: A method of treating chronic kidney disease in a mammalian subject by administering a composition that includes L-arginine, glycine, L-glutamine, L-histidine, L-aspartic acid L-glutamic acid, and L-carnosine.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: June 2, 2020
    Assignee: BIO HEALTH SOLUTIONS, LLC
    Inventor: James Archer
  • Patent number: 10660861
    Abstract: Currently available glutaminase inhibitors are generally poorly soluble, metabolically unstable, and/or require high doses, which together reduce their efficacy and therapeutic index. These can be formulated into nanoparticles and delivered safely and effectively for treatment of pancreatic cancer and other glutamine addicted cancers. Studies demonstrate that nanoparticle delivery of BPTES, relative to use of BPTES alone, can be safely administered and provides dramatically improved tumor drug exposure, resulting in greater efficacy. GLS inhibitors can be administered in higher concentrations with sub-100 nm nanoparticles, since the nanoparticles package the drug into “soluble” colloidal nanoparticles, and the nanoparticles deliver higher drug exposure selectively to the tumors due to the enhanced permeability and retention (EPR) effect. These factors result in sustained drug levels above the IC50 within the tumors for days, providing significantly enhanced efficacy compared to unencapsulated drug.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: May 26, 2020
    Assignee: The Johns Hopkins University
    Inventors: Justin Hanes, Barbara S. Slusher, Anne Le, Jie Fu, Qingguo Xu
  • Patent number: 10660826
    Abstract: The present invention relates to a solid makeup and/or care cosmetic composition in the form of a compact powder, comprising, in a physiologically acceptable medium, at least: one pulverulent phase, one organopolysiloxane elastomer, one emulsifying system, one hydrophilic gelling agent, and one organic non-volatile oil present in a content of greater than or equal to 1% by weight relative to the total weight of the composition. The invention also relates to an intermediate composition for the preparation of such a cosmetic composition, to a process for manufacturing this cosmetic composition, and to a process for coating the skin with the said cosmetic composition.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: May 26, 2020
    Assignee: L'ORÉAL
    Inventors: Anne Simonnet, Stephane Masson
  • Patent number: 10660846
    Abstract: A composition and method for lightening skin includes applying a skin care composition including cell culture extract of Earliella scabrosa. A method for culturing Earliella scabrosa including using an inducer, select carbohydrates and optimal processing condition produces increased skin lightening properties of the cell culture extract.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: May 26, 2020
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Bee Khim Cow, Chong Jin Loy, Thidarat Nimchua, Juthamas Suwanprateep
  • Patent number: 10661095
    Abstract: Disclosed is the use of copper cysteamine nanoparticles for use in photodynamic cancer therapy. The disclosed methods of treatment utilize microwave radiation as a means for activating the copper cysteamine photosensitizer.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: May 26, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Wei Chen, Lun Ma
  • Patent number: 10660869
    Abstract: The present invention relates to a lactate powder, more particularly a lactate powder having a lactate content of at least 20 wt. % and a water content of less than 3.5 wt. %, said powder comprising calcium cations as well as sodium cations. According to the invention, a calcium lactate powder combining high stability with excellent water dissolution properties can be obtained even though anhydrous calcium lactate represents the bulk of the powder if the powder additionally contains a certain amount of sodium lactate. The inventors have found that the presence of sodium lactate greatly improves the dissolution behavior of the anhydrous calcium lactate while maintaining the storage stability of the powder. The present inventors also established that the dissolution behavior of the powder can be further improved by the addition of a fast-dissolving carbohydrate material.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: May 26, 2020
    Assignee: PURAC BIOCHEM B.V.
    Inventors: Kees Van Der Voort Maarschalk, Heny Kusumawardani
  • Patent number: 10662395
    Abstract: The present invention relates to the field of perfumery and more particularly to the field of malodor counteractancy. In particular, it relates to the use of glycerol carbonate or glycerol carbonate derivatives to neutralize the odor from ammonia and primary or secondary amines. Perfuming compositions and perfuming consumer products comprising those malodour neutralizers are also objects of the invention.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: May 26, 2020
    Assignee: Firmenich SA
    Inventors: Pascal Beaussoubre, Wolfgang Fieber
  • Patent number: 10653717
    Abstract: Disclosed herein are antibiotic compositions, for example compositions that comprise a metal-containing agent and an organoselenium agent, and uses thereof.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: May 19, 2020
    Inventors: Arne Holmgren, Jun Lu, Lili Zou
  • Patent number: 10653623
    Abstract: The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: May 19, 2020
    Assignee: Cristcot LLC
    Inventors: Jennifer J. Davagian, Raj Devarajan
  • Patent number: 10653709
    Abstract: A graft copolymer having drug-containing side chains is described. The graft copolymer can be prepared, for example, by directly polymerizing a drug-containing monomer on multiple sites of a linear copolymer. When exposed to water, the graft copolymer can form uniform nanocarriers, e.g., nanomicelles, optionally encapsulating additional drugs, e.g., non-covalently in the interior of the nanocarriers, for coordinated drug delivery of a plurality of drugs. Also described herein is the use of the nanocarriers for delivery of therapeutic agents, particularly the dual delivery of chemotherapeutic agents to treat tumors.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: May 19, 2020
    Assignee: North Carolina State University
    Inventors: Zhen Gu, Wanyi Tai
  • Patent number: 10653141
    Abstract: Compositions and methods for affecting dipteran hematophagous parasites. The compositions contain at least one dipteran semiochemical and at least one phagostimulant. The compositions may further include a pesticide. The semiochemical may be a floral attractant and the phagostimulants may be sugar-based. The compositions may be useful in attracting mosquitoes and/or repelling sand flies.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: May 19, 2020
    Inventors: Agenor Mafra-Neto, Rodrigo Oliveira Da Silva, Carmem R. Bernardi